FEops HEARTguide LAA workflow integrated into TeraRecon software

FEops HEARTguide

FEops has entered into a partnership with ConcertAI’s TeraRecon for the commercialisation of FEops HEARTguide’s for left atrial appendage (LAA) occlusion workflow, with a focus on the US market.

“We are thrilled to join forces with TeraRecon and integrate our FEops HEARTguide solution into TeraRecon’s software,” said Matthieu De Beule, CEO of FEops. “This collaboration is a testament to our shared vision of leveraging technology to transform healthcare. By bringing FEops HEARTguide’s advanced capabilities to TeraRecon’s robust platform, we aim to equip clinicians with a tool that empowers them to provide optimised care to patients with cardiovascular conditions.”

FEops HEARTguide is a cloud-based procedure planning solution in the structural heart space, based on digital twin technology. With the US introduction for the LAA occlusion workflow, FEops HEARTguide enables US physicians to virtually model clinical scenarios with different implant positions and sizes of US Food and Drug Administration (FDA)-cleared LAA devices, aiding physicians in the selection of the optimal size and position for every individual patient, prior to the intervention.

Established clinical evidence from the randomised controlled PREDICT-LAA trial has shown that FEops’ digital twin-based planning for LAA closure results in improved procedure efficiency and outcomes as compared to standard CT based planning.

“The addition of FEops HEARTguide enhances TeraRecon’s comprehensive offerings, particularly in cardiology and cardiovascular care,” said Dan McSweeney, president of TeraRecon. “By integrating FEops’ advanced digital twin AI solution into TeraRecon solutions, we are poised to provide clinicians with an unparalleled tool that streamlines the pre-treatment CT based planning for structural heart interventions, leading to more informed decision making.”

The FEops TeraRecon collaboration represents a significant stride towards personalized and data-driven cardiac care, the companies said in a press release. The fusion of TeraRecon’s solutions and FEops’ HEARTguide solution exemplifies the potential of AI to reshape the future of medical diagnosis and treatment planning.


Please enter your comment!
Please enter your name here